Partnered with ATAI Life Sciences ATAI. Amazing Interview.
"I said there's no way that you can take one dose of Ibogaine and have this complete reset, to use the...
Mike Zapolin, Kevein Harrington and CEO Chad Harman
Another Shark Tank original has invested in the psychedelic industry.
Kevin Harrington, the creator of the...
Above: Lamar Odom and Psychedelic Advocate Mike Zappy Zapolin.
We’re Calling a Sector Bottom, and Psycheceutical (BWVI) as Our Favorite.
We launched...
Depression is one of the most common and most debilitating mental health disorders, affecting some 17 million adults in the US. It also continues to be a misunderstood, often hard-to-treat...
John Hopkins Center for Psychedelic and Consciousness Research
Johns Hopkins University academics just a got a boost in their funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.
After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early stages of a recovery (our opinion) gaining 94%...
Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia
Phase I trial will study 20 people to...
